[
    [
        {
            "time": "2021-03-15",
            "original_text": "Tyvyt速 (Sintilimab Injection) Combined with Gemzar速 (Gemcitabine for Injection) and Platinum Chemotherapy Met the Predefined Primary Endpoint in the Phase 3 ORIENT-12 Study as First-Line Therapy in Patients with Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer",
            "features": {
                "keywords": [
                    "Sintilimab",
                    "Gemcitabine",
                    "Phase 3",
                    "ORIENT-12",
                    "Lung Cancer"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Tyvyt速 (Sintilimab Injection) Combined with Gemzar速 (Gemcitabine for Injection) and Platinum Chemotherapy Met the Predefined Primary Endpoint in the Phase 3 ORIENT-12 Study as First-Line Therapy in Patients with Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-04-28",
            "original_text": "Myriad Genetics (MYGN) Lags Q3 Earnings Estimates, Cancels View",
            "features": {
                "keywords": [
                    "Myriad Genetics",
                    "Q3",
                    "Earnings",
                    "Cancels View"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "genetics"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Myriad Genetics (MYGN) Lags Q3 Earnings Estimates, Cancels View",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-05-06",
            "original_text": "CVS Health (CVS) Q1 Earnings Top Estimates, Costs Escalate",
            "features": {
                "keywords": [
                    "CVS Health",
                    "Q1",
                    "Earnings",
                    "Costs Escalate"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "retail"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "CVS Health (CVS) Q1 Earnings Top Estimates, Costs Escalate",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-05-04",
            "original_text": "Jazz Pharma (JAZZ) Misses on Q1 Earnings & Sales, Cuts View",
            "features": {
                "keywords": [
                    "Jazz Pharma",
                    "Q1",
                    "Earnings",
                    "Sales",
                    "Cuts View"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Jazz Pharma (JAZZ) Misses on Q1 Earnings & Sales, Cuts View",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-05-03",
            "original_text": "Haemonetics (HAE) Q4 Earnings Lag Estimates, Margins Expand",
            "features": {
                "keywords": [
                    "Haemonetics",
                    "Q4",
                    "Earnings",
                    "Margins Expand"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "medical devices"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Haemonetics (HAE) Q4 Earnings Lag Estimates, Margins Expand",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-05-06",
            "original_text": "Inogen's (INGN) Q1 Earnings and Revenues Beat Estimates",
            "features": {
                "keywords": [
                    "Inogen",
                    "Q1",
                    "Earnings",
                    "Revenues",
                    "Beat Estimates"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "medical devices"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Inogen's (INGN) Q1 Earnings and Revenues Beat Estimates",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-05-06",
            "original_text": "DaVita (DVA) Earnings and Revenues Beat Estimates in Q1",
            "features": {
                "keywords": [
                    "DaVita",
                    "Q1",
                    "Earnings",
                    "Revenues",
                    "Beat Estimates"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "dialysis services"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "DaVita (DVA) Earnings and Revenues Beat Estimates in Q1",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-05-04",
            "original_text": "After Its Strong First-Quarter Results, Should You Buy Shares of Eli Lilly?",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "First-Quarter",
                    "Results"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "After Its Strong First-Quarter Results, Should You Buy Shares of Eli Lilly?",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-05-03",
            "original_text": "PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates",
            "features": {
                "keywords": [
                    "PerkinElmer",
                    "Q1",
                    "Earnings",
                    "Revenues",
                    "Surpass Estimates"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "diagnostics"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-05-05",
            "original_text": "Why These 8 Pharma Stocks Are Outplaying 90% Of The Stock Market",
            "features": {
                "keywords": [
                    "Pharma Stocks",
                    "Outplaying",
                    "Stock Market"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Why These 8 Pharma Stocks Are Outplaying 90% Of The Stock Market",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]